ADMA Profile
ADMA Biologics, Inc., a biopharmaceutical company headquartered in Ramsey, New Jersey, specializes in the development, manufacturing, and commercialization of specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. The company offers a range of products including BIVIGAM, an intravenous immune globulin (IVIG) indicated for primary humoral immunodeficiency (PI), and ASCENIV, another IVIG product designed for the treatment of PI. Additionally, ADMA markets Nabi-HB, which is used to treat acute exposure to Hepatitis B surface antigen and other exposures to Hepatitis B.
ADMA Biologics is also advancing a pipeline of plasma-derived therapeutics aimed at addressing various medical needs. This pipeline includes products focused on the treatment and prevention of S. pneumonia infection, leveraging immunoglobulin-based methods. The company's research and development efforts are dedicated to innovating and improving plasma-derived therapies to enhance patient outcomes and address unmet medical needs in both immune deficiency and infectious disease sectors.
In addition to its therapeutic products, ADMA Biologics operates source plasma collection facilities, which play a critical role in ensuring a steady supply of high-quality plasma for its manufacturing processes. These facilities are integral to the company's operations, enabling the collection of plasma that meets stringent safety and quality standards. The collected plasma is then utilized to produce the company's biologic therapies, ensuring consistent availability for patients in need.
ADMA Biologics distributes its products through a network of independent distributors, sales agents, specialty pharmacies, and other alternate site providers, ensuring broad accessibility to its therapies. Incorporated in 2004, the company has steadily grown its presence in the biopharmaceutical industry, driven by a commitment to advancing patient care through innovative plasma-derived treatments. By maintaining rigorous standards in both development and distribution, ADMA Biologics aims to deliver effective and reliable therapies to patients worldwide.
|
